COIOSDeep risk insights through multi-disciplinary research across the globe
a room filled with lots of shelves filled with boxes and boxes
Item new Peer-reviewed Added

Photo review found compounded products in a quarter of surveyed US GLP-1 users

Blinded review of medication photographs classified 25.8% of 322 US adults on weekly semaglutide or tirzepatide as using compounded products, with self-report agreeing for 82.6%.

US adults recruited online who reported at least three months of weekly semaglutide or tirzepatide submitted a photograph of their medication for blinded coding. Among 322 participants, self-report and photo coding agreed for 82.6%, with a kappa of 0.78. Photo review classified 25.8% as using compounded products, two thirds of whom had self-reported one of the branded formulations.

Why it is interesting: Two thirds of those coded as compounded users had named a branded product when asked.

Source
Obesity Science & Practice, 22 September 2026
Paper
Improving Medication Classification in GLP-1RA Research: Feasibility of a Photo-Review Protocol
Authors
Katz JM, Gearhardt AN, Griauzde DH
DOI
10.1002/osp4.70200
Type
Peer-reviewed article
Design
Online survey with blinded photo validation of medication, US adults on weekly semaglutide or tirzepatide ≥3 months, n=322 analytic sample
Verdict
New finding
Driver
Obesity, diabetes and GLP-1
Free full text
Free to read at the publisher
Abstract — the authors' own words, CC BY

Objective

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are dominating the type 2 diabetes and obesity intervention landscape, yet their real-world use is increasingly difficult to characterize amid widespread availability of non-FDA-approved, compounded products obtained outside traditional healthcare systems. These users may not be captured by the clinical and claims databases commonly used in real-world GLP-1RA research. Online surveys offer a scalable alternative for reaching this population; however, existing survey studies depend on self-reported medication use, the reliability of which has not been well characterized. Methods

An online study was conducted among U.S. adults recruited via Prolific who reported ≥ 3 months use of once-weekly injectable semaglutide or tirzepatide. Participants completed a screening survey requiring a photo of the prescribed GLP-1RA, followed by a main survey for eligible participants assessing self-reported GLP-1RA type and sociodemographic and health characteristics. Two blinded, independent coders classified photos as one of four FDA-approved branded formulations or a compounded product; discrepancies were resolved by the second author. Agreement was assessed using Cohen's kappa. Results

Of the 419 screening survey participants, 322 participants comprised the analytic sample; 22 of the total exclusions were based on medication photo review. Self-reported and photo-coded medication types showed substantial agreement (82.61%; Cohen's κ = 0.78, 95% CI [0.73, 0.83]). Photo review classified 83 participants (25.78%) as using compounded GLP-1RAs; among these, 54 (65.06%) self-reported using one of the four branded GLP-1RAs and 29 (34.94%) selected a "none of the above" response option, operationalized as compounded use. Conclusions

This study demonstrated that photo review may be a feasible method for improving medication classification in research and offered recommendations for future studies. Additional work is needed to evaluate this protocol in larger and more diverse samples and to refine formulation-specific self-report items.

Other drivers in Health today